Cx 601

Drug Profile

Cx 601

Alternative Names: Adipose-derived allogenic stem cell therapy - TiGenix; Cx601; eASC therapy - TiGenix

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator Cellerix
  • Developer La Fundacion para la Investigacion Biomedica del Hospital Universitario La Paz; TiGenix
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rectal fistula
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Rectal fistula
  • No development reported Rectovaginal fistula

Most Recent Events

  • 09 Apr 2017 Updated efficacy and adverse events data from the phase III ADMIRE-CD trial in Rectal fistula released by TiGenix
  • 06 Apr 2017 Takeda plans to launch Cx 601 in the European markets in 1H 2018
  • 06 Apr 2017 IND submission and start of recruitment in phase III studies planned in 1H 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top